clinical practice guidelines

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference

Approved by the ESMO Guidelines Working Group: April 2002, last update February 2010. This publication supercedes the previously published version—Ann Oncol 2009; 20 (Suppl 4): iv156-iv158.

Conflict of interest: Dr Roila has reported that he is a member of the advisory board for Helsinn SA, that in the last years he participated in researches sponsored by GSK, Merck Sharp & Dhome and Helsinn and that he has been a speaker at satellite symposia for GSK, Merck Sharp & Dhome and Helsinn; Dr Herrstedt has reported that he is a member of the speakers’ bureau for Merck; Dr Aapro has reported that he is a consultant for Helsinn, Merck, Novartis, Roche and Sanofi-Aventis; Dr Gralla has not reported any conflicts of interest; Dr Einhorn has reported that he holds stock in GlaxoSmithKline; Dr Ballatori has reported no conflicts of interest; Dr Bria has reported no conflicts of interest; Dr Clark-Snow has reported no conflicts of interest; Dr Espersen has reported no conflicts of interest; Dr Feyer has reported no conflicts of interest; Dr Grunberg has reported that he has served as a consultant to Helsinn, Merck, GlaxoSmithKline, SNBL and Prostrakan, he holds stock in Merck and has received lecture honoraria from Merck; Dr Hesketh has reported that he has received research funding from Eisai and Merck and that he serves as consultant on the advisory boards of Helsinn, Merck and GlaxoSmithKline; Dr Jordan has reported that she is a member of the speakers’ bureau of MSD and Helsinn; Dr Kris has reported that he serves as a consultant to Merck and GlaxoSmithKline; Dr Maranzano has reported no conflicts of interest; Dr Molassiotis has reported that he has received honoraria from Roche UK Ltd, Merck, GlaxoSmithKline, Bayer-Schering and research grants from Roche UK Ltd and Merck; Dr Morrow has reported that he is a speaker for EISAI; Dr Olver has reported no conflicts of interest; Dr Rapoport has reported that he is a member of the Merck antiemetic advisory board; Dr Rittenberg has reported no conflicts of interest; Dr Saito has reported no conflicts of interest; Dr Tonato has reported no conflicts of interest; Dr Warr has reported that he is a member of the speakers' bureau and a consultant for Merck.